

Zembrin[®]

PATENTED
STANDARDISED
BOTANICAL
SCELETIUM
INGREDIENT

AN ANCIENT
BOTANICAL
WITH MODERN
APPLICATIONS
FOR MENTAL
WELLNESS



PHARMACEUTICALS
(PTY) LTD

CONTENTS

Introduction	3
Who is impacted? Inside the numbers	4
Zembrin® to the Rescue	6
What is Zembrin® ?	6
What makes Zembrin® different to Kanna?	7
The proof is in the Science	9
What makes ZEMBRIN® tick? Mechanisms of Action	12
Stress/Mood Products are not all equal	12
What makes ZEMBRIN® different from other Mental Wellness Ingredients?	13
Feel Good while you are Feeling Good	15
It's okay to Brag	17
Outside the box formulating with ZEMBRIN®	18
Regulatory	19
Summary: Putting a Bow on ZEMBRIN®	19
References	20



While modern medicine often focuses on mental illness,
it is time for us to focus on improving mental wellness.

Poor mood, declining cognition, stress and anxiety
are the areas of high concern.

**The relation between these areas is tightly connected
in the following ways:**

- Stress/anxiety decreases cognitive function, learning and memory.¹
- A person may have trouble with cognitive function, not realising that it is worry (stress and anxiety) that is impacting their mental performance.
- When we have trouble focusing or concentrating, we often feel stressed or anxious.

As if this was not bad enough, poor mental wellness can impact most aspects of our lives, including cardiovascular health,¹ the immune system,² gastrointestinal problems,¹ hormone issues,¹ weight control,³ elevated blood sugar⁴ and pain,⁵ not to mention our relationships, difficulties at work, home, school and many other areas.


Who is impacted? Inside the numbers

In short, we are all impacted by stress and other mental wellness struggles. This is highlighted by the stress and anxiety statistics which may be exacerbated by events such as the COVID-19 pandemic.

Stress and Anxiety

Pre-pandemic

- In 2017, 44 % of Americans surveyed frequently experienced stress in their daily lives.⁶
- 54 % of people aged 18 to 29 frequently experienced stress.⁶
- In 2019, about one-third of people globally reported feeling stressed, worried and/or angry.⁷
- 49 % of women frequently experienced stress.⁶
- 10 % of people were affected by anxiety in North America, Western Europe and Australia/New Zealand.⁸



While stress and anxiety have become the elephant in the room, mood and cognition issues also impact millions of people and are significant mental wellness concerns.

Effect of the COVID-19 pandemic

- Nearly 80 % of Americans said that the COVID-19 pandemic was a significant source of stress in their lives.⁹
- There was a significant increase in mental health problems in the general population in the first year of the pandemic.¹⁰
- Each of the following was reported to have been experienced by about half of working adults globally because of the COVID-19 pandemic:¹¹
 - Stress due to changes in work routines and organisation, increased by 55 % globally
 - Stress due to family pressures such as childcare, increased by 45 % in South Africa, 64 % in Saudi Arabia and 18 % in the Netherlands.
- Nearly one in five adults said their mental health was worse in 2020 than in 2019.¹²
- The World Health Organization claimed that the COVID-19 pandemic triggered a 25 % increase in the prevalence of anxiety and depression worldwide.¹³

continued overleaf...



Mood

- The COVID-19 pandemic triggered a 25 % increase in mood issues worldwide.¹³
- Nearly one in five Americans have a problem with mood disorders.¹⁴

Nine hundred and seventy million represents the number of people globally with any mood type disorder.¹⁵



Cognition

- Globally the estimated number of people with dementia will increase from 47 million in 2015 to more than 140 million in 2050.¹⁶
- Sixteen million Americans are living with Cognitive Impairment.¹⁷
- One in nine Americans aged 45 and older say they are experiencing declines in thinking ability.
- Among those aged 45 and older who were living alone, 14 % said they were suffering from declines in mental function.¹⁸

ZEMBRIN® to the rescue



Zembrin® to the Rescue


This ancient South African botanical ingredient sourced from *Sceletium tortuosum* and/or *Sceletium crassicaule* is trademarked and marketed as **Zembrin®**.

The numbers mentioned previously are a driving force as to why **Zembrin®** should be a top consideration for inclusion in mental wellness products. It answers many of the world's most pressing mental wellness needs. For a millennium, *Sceletium* plants have been consumed by the San and Khoi people of South Africa for its stress-relieving and mood-enhancing properties. Even today, these indigenous people hold this remarkable botanical in great esteem. In the last several decades, modern medicine has sought to uncover what makes this plant so unique.

This paper will examine why **Zembrin®** is considered a gold standard for those seeking a cutting-edge mental wellness ingredient.



Sceletium use was reported from 1685



What is Zembrin®?

Simply put, **Zembrin®** is derived from the succulent *Sceletium* plants (*Sceletium Tortuosum* (L) N.E. Br & *Sceletium Crassicaule* (Haw.) L. Bolus), native to South Africa. These plants have green leaves and blooms with white and yellow flowers. The name is derived from the Latin word "sceletus" (meaning skeleton) because the prominent veins on the dried leaves give the plant a skeletal appearance.¹⁹



History of *Sceletium* spp.

The use of this plant dates back at least one thousand years. Historically, the plant was used by native San hunter-gatherers and Khoi people to quench their thirst, fight fatigue and for healing, social and spiritual purposes.

The first recorded knowledge of the *Sceletium tortuosum* plant came from Dutch explorers in 1610. Still, the San people and the Khoikhoi people used "Kanna" in the ancient pre-history of the African continent.

The Dutch explorers and traders found the plant so valuable that they named it in their Dutch language as "kougoed" and traded it in the Far East.²⁰

Photos are taken from Waterhouse G, De Wet GC, Pfeiffer RH. 1979. Simon van der Stel's Journey to Namaqualand in 1685. Human & Rousseau, Cape Town and Manuscript reference: ms bc151-c4.3.1..006, University of Cape Town Libraries, Special Collection, Bleek and Lloyd archives.

What makes **Zembrin**[®] different to Kanna?

The name “Kanna” tends to be thrown around loosely the same way that most people use the name “Kleenex[®]” as a generic term for tissue. Yet not all tissues are the same i.e. some are rough, thin, some have moisturising properties etc. The same holds true with regards to **Zembrin**[®] and its connection to the name Kanna. The chart below explains why **Zembrin**[®] should never be regarded as being “Kanna”.

	Kanna Generic term for <i>Sceletium</i> products	Zembrin [®] Patented and trademarked <i>Sceletium</i> extract
Phytochemical make-up	Zero guarantee that the product contains the beneficial alkaloids	Standardised alkaloid profile for each batch
Levels of psycho-active alkaloid Mesembrine	High risk of high levels of mesembrine	No risk of having high levels of mesembrine
Studied	Not clinically studied	Most clinically studied <i>Sceletium spp.</i> extract (8 double-blind, placebo-controlled studies...and counting)
Dosing	Can range from 200 mg to 500 mg	Clinically proven dose of 25 mg
Use	Used recreationally for its euphoric effect	Used to help with mood, stress, anxiety and cognition
Growing and Harvesting Technique	Usually wild-harvested and uncontrolled growing	Sustainable and scalable cultivation. HG&H Pharmaceuticals has a bioprospecting permit and fulfills the conditions set out in the Nagoya protocol
Social Responsibility	No social responsibility programmes in place	Royalties paid to the communities whose indigenous knowledge contributed to the development of Zembrin [®]

continued overleaf... >



Zembrin® is unique

Zembrin® is the **only patented, standardised and clinically studied** *Sceletium spp.* extract on the market. Zembrin® contains a unique alkaloid content and composition of the four alkaloids: mesembrine, mesembrenone, mesembrenol and mesembranol. It took five years to select the correct species of *Sceletium* and ensure that the required horticultural practices were honed to grow the crop. Special care was taken to make the proprietary selection of the non-GMO *Sceletium spp.* used in the production of Zembrin®



Zembrin® is cultivated exclusively for HG&H Pharmaceuticals (Pty) Ltd (the proprietary owners of Zembrin®) and no others.

The unique chemical fingerprint of Zembrin® is quantified with a wide range of analytical methods, including botanical matching (DNA identification), HPTLC and HPLC.

Other products referred to as Kanna do not come close to this meticulous process.

HPTLC = high performance thin layer chromatography.
HPLC = high performance liquid chromatography.



The proof is in the Science

Nothing speaks louder than science! Considerable time, effort and money have been spent on substantiating the safety and efficacy of **Zembrin**[®]. Due to uniqueness of **Zembrin**[®], as mentioned on the previous page, comprehensive preclinical and clinical studies have been carried out. Below you will find summaries of the clinical studies conducted to date.

Toxicity

A study²¹ published in *Food and Chemical Toxicology* evaluated the potential toxicity of **Zembrin**[®]. A 14-day trial was performed with rats given up to 5000 mg/kg bw/day, while a 90-day study administered up to 600 mg/kg bw/day of **Zembrin**[®]. In the 14-day study, there were no mortalities, and the rats exhibited normal behavioural and physical conditions with no significant abnormalities in clinical signs. The 90-day study concluded that there were no observed adverse effect levels, no mortalities and the rats exhibited normal behavioural and physical conditions with no significant abnormalities in clinical signs. **These results confirm the absence of any acute or chronic toxicity of Zembrin**[®].



Safety and Tolerability in Humans

A published human clinical trial²² was completed to evaluate the safety and tolerability of two doses (8 mg and 25 mg once daily) of **Zembrin**[®] in healthy adults. The research showed that both doses of **Zembrin**[®] were well tolerated. In addition, there were **no apparent differences in vital signs, physical examination, ECG, body weight, haematology or biochemistry parameters** from beginning to end.

Applying a 100-fold uncertainty factor to compensate for inter- and intra-species differences, results can be extrapolated to an acceptable daily intake of **420 mg by a 70 kg human** (well above the suggested daily intake of **25 mg per day**). **Zembrin**[®] is well tolerated.



continued overleaf... >

Efficacy

Mood, stress and anxiety

With regards to effectiveness, the study²² mentioned above in "Safety and Tolerability" also showed unsolicited positive effects on well-being in patient diaries among some participants taking **Zembrin**[®], including **improved coping with stress and sleep difficulties**. While this is not a definitive clinically proven impact, it is worth noting as the following studies will add to these observations.

Ideally, either stopping stress where it starts in the brain, or being able to slow down the process of feeling its effects would be the best approach to managing stress. Stressful events trigger a response from the amygdala and hypothalamus (considered to be the stress centre of the brain). One study²³ looked at the effectiveness of a single dose of **Zembrin**[®] in using fMRI to reduce anxiety-related amygdala reactivity and amygdala-hypothalamus coupling. The results showed that **Zembrin**[®] reduced amygdala reactivity and "decoupled" amygdala-hypothalamus connectivity. This impact slows and/or decreases the impact of stressful events in the brain and proves the anti-anxiety effects of **Zembrin**[®].

Two other studies using a double-blind, placebo-controlled design evaluated the effects of a single dose of **Zembrin**[®] (25 mg) on laboratory stress and anxiety in 20 healthy volunteers.²⁴ In the first study, participants completed 20 minutes of multitasking, and in study 2, participants completed a 5 minute simulated public speaking task. The results showed that when both studies were "Taken together, **results indicate that a single dose of Zembrin**[®] **can ameliorate laboratory stress/anxiety response in healthy volunteers**".²⁴

Cognition effects

A study²⁵ with 21 cognitively healthy adults examined the neurocognitive effects of **Zembrin**[®] and assessed the safety and tolerability of **Zembrin**[®]. Each participant took 25 mg of **Zembrin**[®] daily for three weeks in a randomised placebo-controlled three week cross-over design. **Zembrin**[®] **had significantly improved cognitive set flexibility and executive function compared with the placebo group. In addition, positive changes in mood and sleep were found. Zembrin**[®] **was also well tolerated.**

Another study²⁶ with 60 healthy volunteers consuming either a 25 mg or 50 mg dose of **Zembrin**[®] evaluated its impact on the brain's electrical activity during cognitive processing and emotional challenges. The results showed that, in comparison to the placebo, **Zembrin**[®] **induced frequency changes in the brain, which have been related to enhanced attention and memory.** These results may represent a **positive action of Zembrin**[®] **on cognitive and emotional processes in the brain.** Additionally, **a greater degree of calmness and memory can be extrapolated** from the increases in alpha2 waves.

continued overleaf...



Active/Sports Nutrition

A study²⁷ designed to investigate the use of **Zembrin**[®] on muscle soreness, markers of muscle damage, mood and exercise performance following unaccustomed resistance exercise in 16 untrained women showed that short-term **Zembrin**[®] supplementation resulted in lower perceived soreness and greater preservation of a range of motion versus results seen in the placebo group.

While mood worsened from baseline in all groups, the group taking **Zembrin**[®] did not decline as much as the placebo group. The researchers concluded that **Zembrin**[®] supplementation might effectively reduce the markers of soreness and preserve mood, following unaccustomed eccentric exercise.

Science Summary

In all, eight pilot double-blind, placebo-controlled clinical studies in healthy people have been completed and published,^{22-27,57,58} paving the way for future larger clinical trials in patient populations.

- **Positive effects on wellbeing** were noted by participants taking **Zembrin**[®], including **improved coping with stress, anxiety and mood disorders.**
- **Zembrin**[®] has been proven to **positively impact the electrical activity of the brain only two hours after ingestion** and significantly improve key cognitive domains i.e. cognitive flexibility and executive function.
- In a groundbreaking pharmaco-functional magnetic resonance imaging (fMRI) study, **Zembrin**[®] was found to have **significant anti-anxiety activity after a single dose.**



- **Zembrin**[®] has been proven to decrease perceived soreness following exercise, to preserve range of motion following exercise, to reduce perceived exertion and to prevent exercise-related mood disturbances.

More Science is Coming

A new clinical trial has commenced at the Brain, Performance and Nutrition Research Centre, Faculty of Health and Life Sciences of Northumbria University, UK, under the supervision of Professor David Kennedy. The clinical trial will evaluate the psychological effects of eight weeks supplementation with **Zembrin**[®]: a randomised, double-blind, placebo-controlled, parallel group trial. **This study will be the first large-scale trial involving Zembrin**[®].

What makes ZEMBRIN® tick? Mechanisms of Action

Zembrin® has a **patented, unique dual mode of action** as a potent inhibitor of 5-hydroxytryptamine (5-HT) reuptake and phosphodiesterase-4 (PDE4) activity. The advantage of dual inhibition of 5-HT uptake and PDE4 is rapid onset of action and the synergistic activity allowing low doses to be used with excellent tolerability. The study mentioned previously regarding the fMRI results validated these two mechanisms of action.²³

A paper published in the *Journal of Ethnopharmacology*²⁸ conducted broad pharmacological profiling of Zembrin®, which confirmed a unique dual mode of action as being a potent blocker of 5-HT and having powerful inhibitory effects on PDE4.

The study showed that:

- the alkaloid mesembrine was the most active against 5-HT, while
- the alkaloid mesembrenone was active against both the 5-HT transporter and PDE4.



Stress/Mood Products are not all equal



Looking at any health food store's "stress/mood" section can make your head spin. Which ingredient should be taken for what?

What makes Zembrin® different to the abundance of other stress ingredients in the market?

Simply put, we need to look at:

- the mechanisms of action
- the dose required
- the time it takes to work (onset), and
- the side effect profile.

continued overleaf...



What makes ZEMBRIN® different from other Mental Wellness Ingredients?

The table below lists some of the commonly used ingredients for stress and their dose, mechanisms of action, onset and any precautions in **red**.

Ingredient	Dose	Mechanism of action	Onset
Zembrin®	25 mg	Neurotransmitter support <ul style="list-style-type: none"> phosphodiesterase-4 (PDE4) and serotonin (5-HT) reuptake inhibition.²³ Impact on the amygdala (stress centre of the brain).	2 hours
5-HTP	150 mg - 800 mg	Neurotransmitter support <ul style="list-style-type: none"> increases the production of serotonin by the central nervous system.²⁹ 	Unknown
Ashwagandha	125 mg - 600 mg	Adaptogenic Neurotransmitter support <ul style="list-style-type: none"> suppresses stress-induced increases of dopamine receptors in the corpus striatum of the brain.³⁰ enhances serotonergic transmission through modulation of the postsynaptic serotonin (5-HT) receptors.³¹ 	Weeks to Months
Bacopa	300 mg	Adaptogenic Neurotransmitter support <ul style="list-style-type: none"> inhibits acetylcholinesterase activity.³² 	Weeks to Months
CBD/Hemp	???	More research is needed.	Unknown
GABA	100 mg - 200 mg up to 3x per day	Exerts both sedative and anxiolytic effects ^{59,60} <ul style="list-style-type: none"> effects at the cellular level.^{59,60} 	1 - 2 hours
Holy Basil	500 mg	Adaptogenic	Weeks to Months
Lactium®	150 mg - 300 mg	Neurotransmitter support <ul style="list-style-type: none"> stimulates activity of the GABA neurotransmitters.⁶² 	7 - 15 days

continued overleaf... >



Ingredient	Dose	Mechanism of action	Onset
Lemon Balm	Limited Research	Unknown MOA <ul style="list-style-type: none"> Clinical research suggests that lemon balm induces a calming effect and reduces alertness.³⁴ **Causes drowsiness**	Unknown
L-Theanine	50 mg - 200 mg	Inhibits glutamate reuptake⁶³ Glutamate receptor antagonist <ul style="list-style-type: none"> has effects on glutamate receptors and the possibility it increases inhibitory neurotransmitters such as glycine or gamma-aminobutyric acid (GABA).³³ inhibits the reuptake of glutamate⁶³ and is a glutamate receptor antagonist in the hippocampus.⁶⁴ 	8 - 10 hours
Rhodiola	340 mg	Adaptogenic and supports the neurotransmitters involved in the stress response by the nervous system³⁵⁻³⁷	Weeks to Months
Saffron	28 mg - 30 mg	Supports the balance of neurotransmitters involved in the stress response by the nervous system: <ul style="list-style-type: none"> inhibits reuptake of dopamine, norepinephrine and serotonin.^{38,39} 	1 - 2 hours
Valerian	300 mg - 600 mg	Neurotransmitter support <ul style="list-style-type: none"> impacts on GABA and Serotonin receptors. May bind directly to the GABA-a receptor.^{40,41} **Causes drowsiness**	1 - 2 hours

It is significant to note that when addressing stress, most consumers are looking for something that “takes the edge off”, while not negatively impacting their quality of life. For decades, the ingredients which work quickly have often come with unwanted side effects such as drowsiness and fatigue. The most popular “fast-acting” ingredients for stress are passion flower, valerian and kava, and all

three come with drowsiness as a side effect. **Zembrin®**, on the other hand, is fast-acting (starts working within two hours)⁵⁷ and no reports have been made about **Zembrin®** causing drowsiness. Looking at the table above, **Zembrin® provides benefits across the board, at a low dose, is fast acting and has no known adverse effects.**²²⁻²⁷

Feel Good while you are Feeling Good

As we can see, **Zembrin**[®] offers a “feel good” effect by improving the three critical areas of mental wellness – stress and anxiety, mood and cognition.

If you need more reasons to “feel good” about **Zembrin**[®], it is **vertically integrated and traceable** and has a tremendous “feel good” **social responsibility and sustainability story**.

In 2009, **Zembrin**[®] was awarded the first Integrated Export and Bioprospecting Permit by South Africa’s Minister of Water and Environmental Affairs in Pretoria, South Africa, **in recognition of its environmentally sustainable production and socially responsible indigenous benefit-sharing agreement**.

Social Responsibility



- A royalty is paid to the South African San Council on all **Zembrin**[®] sold, in recognition of the contribution of their indigenous knowledge to the development of **Zembrin**[®].
- This was formalised through a groundbreaking benefit-sharing agreement signed in February 2008 between HG&H Pharmaceuticals (Pty) Ltd and the South African San Council to support both the Paulshoek and Nourivier communities in the Northern Cape Province of South Africa.
- The royalties are used for educational purposes, assisting parents who cannot afford school uniforms and school fees, and to fund farming and agricultural projects.

continued overleaf... >

Sustainability with a Twist

Sceletium spp. are a protected species, and wild harvesting is not sustainable for commercial products. Realising this, HG&H Pharmaceuticals (Pty) Ltd are **committed to using only cultivated plant material** in the production of **Zembrin®** to avoid depleting threatened wild plant stocks and ensure consistent product quality.

The process to achieve Sustainability

Zembrin® is the result of many years of research into the botany, chemistry, selection and cultivation of *Sceletium*. Initial fieldwork found that indigenous people could point out locations where traditionally used *Sceletium* plants were regarded as 'strong' and potentially euphoria-inducing. In contrast, adjacent sites with identical-looking *Sceletium* plants were considered to be 'mild' and used for stress.

Analytical work determined that the euphoria-inducing plants were exceptionally high in the alkaloid mesembrine. These plants are typically fermented traditionally to enhance even further the euphoriant potential. Analytical work was also carried out

using the "mild" plants which showed they had a lower total alkaloid content, and the alkaloid composition was low in the alkaloid mesembrine.

To have a safe, reproducible, "mild" product suitable for functional foods and supplements, seed stock for the cultivation of **Zembrin®** was taken from the plants with **low alkaloid** content and **low mesembrine** composition. All subsequent work aimed to maintain a large gene pool of plants with the responsible alkaloid content and composition.

The process ensured a reproducible raw material suitable for producing a consistent and safe extract. This provides more validation of how **Zembrin® is different from Kanna.**



By investing in a highly successful crop development programme and controlling the seed stock, **Zembrin®** can be produced on a large commercial scale.

DOESN'T SUSTAINABILITY FEEL GOOD?

It's okay to Brag

Here are a few “bragging points” for **Zembrin®**:

- An international best practice benefit-sharing agreement exists with the South African San Council.
- **Zembrin®** is the only *Sceletium spp.* extract endorsed by the South African San Council.
- Recipient of the first ever export permit from the South African government, full compliance under the Biodiversity Act.
- Biodiversity leadership was hailed at the United Nations Nagoya conference by the South African Minister of the Environment.
- Plant production and cultivation are ecologically sustainable and conform to the European Union and Global Good Agricultural Practices.
- Reliable supply chain and validated quality control are ensured through own propagation and production.



Vertical Integration

Clearly and simply put, **Zembrin®** is vertically integrated from the SEED to the EXTRACT. Controlling all steps from the proprietary seeds, growing location, growing practices and extraction is essential to ensuring a quality finished ingredient. **Zembrin® offers peace of mind with its fully traceable vertical integration.**



ZEMBRIN® is Award Winning

- The Functional Ingredients Magazine Editor's Choice Award was given to **Zembrin®** for the 2013 most sustainable ingredient.
- The Indigenous Plant Use Forum gave **Zembrin®** the Best Product award in 2013.

ZEMBRIN® is Patented and Trademarked

Zembrin® is patent protected by international patents and new patent applications in several countries, including Australia, Europe (Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland), Ireland, India, South Africa, Turkey, United Kingdom and the USA. **Zembrin®** is also trademark registered as Zembren® (Malaysia), Zenbrin® (Japan) and Eletium®.



Outside the box formulating with ZEMBRIN®

Stress is recognised as being a risk factor for other health challenges we all may face. When formulating for success, strong consideration for adding a successful stress and anxiety ingredient can add value and differentiation from other formulations.

The following areas of health have stress, anxiety and mood as contributing risk factors:¹

- **Cardiovascular health**
- **Memory**
- **Concentration**
- **Blood sugar control**
- **Sleep**
- **Gastrointestinal Health** ^{2,42-46}
 - digestion and absorption of nutrients into the body
 - changes in gut bacteria
 - GERD
 - Dyspepsia (abdominal pain-upper middle part of the stomach)
 - erosion of the digestive lining.
- **Immune weakness** ²
- **Skin Health** ⁴⁷
 - Acne
 - Hair loss
 - Hair thinning
 - Eczema (Atopic dermatitis)
 - Psoriasis
 - Rosacea
 - Scalp rash
 - Hives
 - Slow Healing
- **Fatigue** ⁴⁸
- **Erectile Dysfunction** ^{49,50}
- **Sex Hormone reduction** ^{51,52}
- **Decreased sexual desire** ⁵³
- **Pain** ^{54,55}
- **Headaches** ⁵⁶



Due to the connection between stress and anxiety to cognition issues, the addition of **Zembrin®** to a cognitive formulation would provide a double benefit. Not only does **Zembrin®** show effects directly on cognition, but it is also a powerful agent for dealing with stress and anxiety too. The benefit is a one-two punch for your finished product.

While there is no current research directly connected to using **Zembrin®** for these health concerns above, adding **Zembrin®** to help address the underlying risk factor of stress and anxiety can only help the end-user take a step in the right direction towards better health.

Regulatory

Zembrin[®] is sold in the USA market under self-affirmed GRAS (Generally Recognised As Safe) and has been granted marketing authorisation by Health Canada as a non-prescription natural product with Product License NPN 80088325. **Zembrin**[®] has been registered in India by India's Food Safety and Standards Authority. Additional regulatory submissions are currently underway in other markets.



Samples available on request.

Summary: Putting a Bow on ZEMBRIN[®]

The best way to sum up **Zembrin**[®] is this: **Zembrin**[®] offers many opportunities to make health claims in **cognitive function, stress/ anxiety, mood and sports nutrition**. In addition, a complete claims dossier can be made available for those seeking more in-depth information.

You can also mention the feel-good stories of **social responsibility, sustainability, vertical integration and traceability**. Finally, let's not forget that **Zembrin**[®] is also **experiential**.

Consumers these days want to be able to "feel" their supplements working, and **Zembrin**[®] will give you this offering. Throw in the patents, trademarks, awards and possibilities to market products "outside the box," and you have a clear winner in **Zembrin**[®].

ZEMBRIN[®] is:

- **Great for Mental Wellness** - Stress, anxiety, mood and cognition.
- **The most clinically studied *Sceletium* extract in the world** - Eight pilot, double-blind, placebo-controlled clinical studies.
- **Fast Acting** - Clinically proven to positively impact the electrical activity of the brain only two hours after ingestion.
- **Experiential** - **Zembrin**[®] users feel the difference it makes to their mental well-being, which guarantees repurchase.

- **Low Dose** - Proven safety and efficacy at 25 mg. Great for formulation development as a single ingredient or combination product.
- **Safe** - Researchers have thoroughly studied the safety of **Zembrin**[®].
- **Easily Tolerated** - Yes, safety studies have shown that **Zembrin**[®] is well tolerated.
- **Socially Responsible** - A royalty from every kilogram of **Zembrin**[®] sold is paid to the African tribes that contributed their indigenous knowledge to the development of this patented extract.
- **Ecologically Sustainable** - No wild farming and depletion of indigenous stock.
- **Feel Good Story** - If we were going to pick a slogan for **Zembrin**[®], it might be "Feel good while you're feeling good." **Zembrin**[®] is the mental wellness ingredient with a truly feel-good story.
- **Fully Traceable** - Strict adoption of quality control measures with EU-GMP.
- **Dual Acting** - Research with **Zembrin**[®] has shown that it has a dual mechanism of action.
- **Not a conventional pharmaceutical anti-depressant** - but it helps with uplifting spirits and improving mood.
- **Not a stimulant** - but it helps with alertness and improves mental performance.

References

1. Yaribeygi H, Panahi Y, Sahraei H, *et al.* The impact of stress on body function: A review. *EXCLI J.* 2017;16:1057-1072. doi:10.17179/excli2017-480.
2. Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. *Immunol Res.* 2014;58(2-3):193-210. doi:10.1007/s12026-014-8517-0.
3. van der Valk ES, Savas M, van Rossum EFC. Stress and Obesity: Are There More Susceptible Individuals?. *Curr Obes Rep.* 2018;7(2):193-203. doi:10.1007/s13679-018-0306-y.
4. Wong H, Singh J, Go RM, *et al.* The Effects of Mental Stress on Non-insulin-dependent Diabetes: Determining the Relationship Between Catecholamine and Adrenergic Signals from Stress, Anxiety, and Depression on the Physiological Changes in the Pancreatic Hormone Secretion. *Cureus.* 2019;11(8):e5474. doi:10.7759/cureus.5474.
5. Ahmad AH, Zakaria R. Pain in Times of Stress. *Malays J Med Sci.* 2015;22(Spec Issue):52-61.
6. GALLUP website. Eight in 10 Americans Afflicted by Stress. 20 December 2017. Available at: https://news.gallup.com/poll/224336/eight-americans-afflicted-%20stress.aspx?g_source=ALL_GALLUP_HEADLINES&g_medium=topic&g_campaign=tiles. Accessed: 7 April 2022.
7. GALLUP website. Americans' Stress, Worry and Anger Intensified in 2018. 25 April 2019. Available at: https://news.gallup.com/poll/249098/americans-stress-worry-anger-intensified-2018.aspx?g_source=link_NEWSV9&g_medium=LEAD&g_campaign=item_&g_content=Americans%27%2520Stress%2c%and%2520Anger%2520Intensified%2520in%25202018. Accessed: 7 April 2022.
8. Medical News Today website. Depression Is A World-Wide Problem. 23 July 2012. Available at: <https://www.medicalnewstoday.com/articles/248155#1>. Accessed: 12 October 2020.
9. American Psychological Association website. COVID-19 Is a Significant Stressor for Most Americans. Available at: https://www.apa.org/images/sia-2020-covid-stress_tcm7-279798.jpg. Accessed: 15 September 2022
10. Chang S-S, Stuckler D, Yip P, *et al.* Impact of 2008 global economic crisis on suicide: time trend study in 54 countries. *BMJ.* 2013;347(7925):f5239. doi:10.1136/bmj.f5239.
11. Ipsos. The COVID-19 Pandemic's Impact on Workers' Lives: 28-country Ipsos survey for The World Economic Forum. December 2020. Available at: <https://www.ipsos.com/sites/default/files/ct/news/documents/2020-12/impact-of-the-covid-19-pandemic-on-workers-lives-report.pdf>. Accessed: 19 February 2021.
12. American Psychological Association website. Stress in America™ 2020: A National Mental Health Crisis, (Poll completed between 4 August and 26 August 2020). Available at: <https://www.apa.org/news/press/releases/stress/2020/sia-mental-health-crisis.pdf>. Accessed: 7 April 2022.
13. WHO website. COVID-19 pandemic triggers 25% increase in the prevalence of anxiety and depression worldwide. 2 March 2022. Available at: <https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide>. Accessed: 7 April 2022.
14. The Recovery Village website. Mood Disorders Statistics. 26 May 2022. Available at: <https://www.therecoveryvillage.com/mental-health/mood-disorders/mood-disorders-statistics/>. Accessed: 28 September 2022.
15. Statista website. Mental health worldwide- Statistics and Facts. 28 June 2022. Available at: https://www.statista.com/topics/8066/mental-health-worldwide/#topicHeader__wrapper. Accessed 28 September 2022.
16. Tsai CK, Kao TW, Lee JT, *et al.* Global-cognitive health metrics: A novel approach for assessing cognition impairment in adult population. *PLoS One.* 2018;13(5):e0197691. doi:10.1371/journal.pone.0197691.
17. Family Caregiver Alliance website. Incidence and Prevalence of the Major Causes of Brain Impairment. Available at: <https://www.caregiver.org/resource/incidence-and-prevalence-major-causes-brainimpairment/>. Accessed: 28 September 2022.
18. HealthDay website. Mental Health. Senior Health. 1 in 9 Adults over 45 reports memory problems. 28 May 2022. Available at: <https://consumer.healthday.com/cognitive-health-information-26/memoryproblems-health-news-468/1-in-9-u-s-adults-over-45-reports-memory-problems-735750.html>. Accessed: 28 September 2022.
19. Gericke N, Viljoen AM. Scelletium — a review update. *J Ethnopharmacol.* 2008;119(3):653-663. doi: 10.1016/j.jep.2008.07.043.
20. Gericke N. Kabbo's!Kwaiñ: The Past, Present and Possible Future of Kanna. 2018.
21. Murbach T, Hirka G, Szakonyiné I, *et al.* A toxicological safety assessment of a standardized extract of Scelletium tortuosum (Zembrin®) in rats. *Food and Chemical Toxicology.* 2014;74:190-199. doi: 10.1016/j.fct.2014.09.017.
22. Nell H, Siebert M, Chellan P, *et al.* A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Extract Scelletium tortuosum (Zembrin) in Healthy Adults. *J Altern Complement Med.* 2013;19(11): 898-904. doi: 10.1089/acm.2012.0185.
23. Terburg D, Syal S, Rosenberger LA, *et al.* Acute Effects of Scelletium tortuosum (Zembrin), a Dual 5-HT Reuptake and PDE4 Inhibitor, in the Human Amygdala and its Connection to the Hypothalamus. *Neuropsychopharmacology.* 2013;38:2708-2716. doi:10.1038/npp.2013.183.
24. Reay J, Wetherell MS, Morton E, *et al.* Scelletium tortuosum (Zembrin®) ameliorates experimentally induced anxiety in healthy volunteers. *Human Psychopharmacology.* 2020;35(6):1-7.
25. Chiu S, Gericke N, Farina-Woodbury M, *et al.* Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Scelletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. *Evidence based complementary and alternative medicine.* 2014:682014. doi: 10.1155/2014/682014.
26. Dimpfel W, Gericke N, Suliman S, *et al.* Psychophysiological Effects of Zembrin® Using Quantitative EEG Source Density in Combination with Eye-Tracking in 60 Healthy Subjects. A Double-Blind, Randomized, Placebo-Controlled, 3-Armed Study with Parallel Design. *Neuroscience and Medicine.* 2016;7:114-132. doi: 10.4236/nm.2016.73013.
27. Berry AR, Langley HN, Rogers RR, *et al.* Effects of Zembrin® (Scelletium tortuosum) Supplementation on Mood, Soreness, and Performance Following Unaccustomed Resistance Exercise: A Pilot Study. *Nutraceuticals.* 2021;1(1):2-11. doi: 10.3390/nutraceuticals1010002.
28. Harvey AL, Young LC, Viljoen AM, *et al.* Pharmacological actions of the South African medicinal and functional food plant Scelletium tortuosum and its principal alkaloids. *J Ethnopharmacol.* 2011;137(3):1124-1129. doi: 10.1016/j.jep.2011.07.035.
29. Birdsall TC. 5-Hydroxytryptophan: A clinically-effective serotonin precursor. *Altern Med Rev.* 1998;3(4):271-280.
30. Booth SJ and Upton R. Ashwagandha Root, Withania somnifera: Analytical, Quality Control, and Therapeutic Monograph. Santa Cruz, CA: American Herbal Pharmacopoeia. 2000:1-25.

continued overleaf...



References *continued*

31. Jahanbakhsh SP, Manteghi AA, Emami SA, *et al.* Evaluation of the efficacy of *Withania somnifera* (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized, double-blind placebo-controlled trial. *Complement Ther Med.* 2016;27:25-29. doi: 10.1016/j.ctim.2016.03.018.
32. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *J Altern Complement Med.* 2010;16:753-759. doi: 10.1089/acm.2009.0342.
33. Hidese S, Ota M, Wakabayashi C, *et al.* Effects of chronic L-theanine administration in patients with major depressive disorder: an open-label study. *Acta Neuropsychiatr.* 2017;29(2):72-79.
34. Kennedy DO, Scholey AB, Tildesley NTJ, *et al.* Modulation of mood and cognitive performance following acute administration of *Melissa officinalis* (lemon balm). *Pharmacol Biochem Behav.* 2002;72(4):953-964. doi: 10.1016/s0091-3057(02)00777-3.
35. Darbinyan V, Kteyan A, Panossian A, *et al.* *Rhodiola rosea* in stress-induced fatigue - a double-blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. *Phytomedicine.* 2000;7(5):365-371. doi: 10.1016/S0944-7113(00)80055-0.
36. Kelly GS. *Rhodiola rosea*: A Possible Plant Adaptogen. *Altern Med Rev.* 2001;6:293-302.
37. Chen QG, Zeng YS, Qu ZQ, *et al.* The effects of *Rhodiola rosea* extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. *Phytomedicine.* 2009;16(9):830-838. doi: 10.1016/j.phymed.2009.03.011.
38. Hosseinzadeh H and Noraei NB. Anxiolytic and hypnotic effect of *Crocus sativus* aqueous extract and its constituents, crocin, and safranal, in mice. *Phytother Res.* 2009;23(6):768-774. doi: 10.1002/ptr.2597.
39. Georgiadou G, Tarantilis PA and Pitsikas N. Effects of the active constituents of *Crocus Sativus* L., crocins, in an animal model of obsessive-compulsive disorder. *Neurosci Lett.* 2012;528(1):27-30. doi: 10.1016/j.phymed.2008.06.005.
40. Houghton PJ. The scientific basis for the reputed activity of Valerian. *J Pharm Pharmacol.* 1999;51(5):505-512. doi: 10.1211/0022357991772772.
41. Yuan C-S, Mehendale S, Xiao Y, *et al.* The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. *Anesth Analg.* 2004;98(2):353-358. doi: 10.1213/01.ANE.0000096189.70405.A5.
42. Konturek PC, Brzozowski T and Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol.* 2011;62(6):591-599.
43. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. *Am J Gastroenterol.* 2001;96(2):303-314. doi: 10.1111/j.1572-0241.2001.03511.x.
44. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). *Scand J Gastroenterol.* 1999;231:29-37.
45. Dunn JP and Cobb S. Frequency of peptic ulcer among executives, craftsmen and foreman. *J Occup Med.* 1962;4:343-348. doi: 10.1097/00043764-196207000-00001.
46. Cobb S, Rose RM. Hypertension, peptic ulcer and diabetes in air traffic controllers. *JAMA.* 1973;224(4):489-492.
47. Chen Y and Lyga J. Brain-Skin Connection: Stress, Inflammation and Skin Aging. *Inflamm Allergy Drug Targets.* 2014;13(3):177-190. doi: 10.2174/1871528113666140522104422.
48. Kocalevent RD, Hinz A, Brähler E, *et al.* Determinants of fatigue and stress. *BMC Res Notes.* 2011;4:238. doi: 10.1186/1756-0500-4-238.
49. Lambert EA and Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. *Curr Hypertens Rep.* 2011;13(3):244-248. doi: 10.1007/s11906-011-0186-y.
50. Healthy Mail website, How do stress and anxiety affect sexual performance and erectile dysfunction? May 2020. Available at: <https://www.healthymale.org.au/news/how-do-stress-and-anxiety-affect-sexual-performance-and-erectile-dysfunction>. Accessed: 30 September 2022.
51. Afrisham R, Sadegh-Nejadi S, SoliemaniFar O, *et al.* Salivary Testosterone Levels Under Psychological Stress and Its Relationship with Rumination and Five Personality Traits in Medical Students. *Psychiatry Investig.* 2016;13(6):637-643. doi: 10.4306/pi.2016.13.6.637.
52. Ranabir S, Reetu K. Stress and hormones. *Indian J Endocrinol Metab.* 2011;15(1):18-22. doi: 10.4103/2230-8210.77573.
53. Boston University School of Medicine Sexual Medicine website. Epidemiology of FSD. Available at: <https://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-fsd/>. Accessed: 1 October 2022.
54. American Psychological Association website. Stress Effects on the body. 1 November 2018. Available at: <https://www.apa.org/topics/stress/body>. Accessed: 4 October 2022.
55. Abdallah CG and Geha P. Chronic Pain and Chronic Stress: Two Sides of the Same Coin?. *Chronic Stress (Thousand Oaks).* 2017;1:2470547017704763. doi: 10.1177/2470547017704763.
56. Moon H-J, Seo J-G, and Park S-P. Perceived stress in patients with migraine: a case-control study. *J Headache Pain.* 2017;18(1):73. doi: 10.1186/s10194-017-0780-8.
57. Dimpfel W, Gericke N, Suliman S, *et al.* Effect of Zembrin® on Brain Electrical Activity in 60 Older Subjects after 6 Weeks of Daily Intake. A Prospective, Randomized, Double-Blind, Placebo-Controlled, 3-Armed Study in a Parallel Design. *World J Neurosci.* 2017;7(1):140-171. doi: 10.4236/wjns.2017.71011.
58. Hoffman JR, Markus I, Dubnov-Raz G, *et al.* Ergogenic Effects of 8 Days of *Sceletium Tortuosum* Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women. *J Strength Cond Res.* 2020;34(9):2476-2481. doi: 10.1519/JSC.0000000000003693.
59. Kalant H, Roschlau WHE, Eds. Principles of Medical Pharmacology. New York, NY: Oxford Univ Press, 1998.
60. Bloom FE, Kupfer DJ, Eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd., 1995.
61. Cohen MM. Tulsi - *Ocimum sanctum*: A herb for all reasons. *Journal of Ayurveda and Integrative Medicine.* 2014;5(4):251-259. doi: 10.4103/0975-9476.146554.
62. Kim HJ, Kim J, Lee S, *et al.* A Double-Blind, Randomized, Placebo-Controlled Crossover Clinical Study of the Effects of Alpha-s1 Casein Hydrolysate on Sleep Disturbance. *Nutrients.* 2019;11(7):1466. doi: 10.3390/nu11071466.
63. Sugiyama T, Sadzuka Y, Tanaka K, *et al.* Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin. *Toxicol Lett.* 2001;121(2):89-96. doi: 10.1016/s0378-4274(01)00317-4.
64. Wakabayashi C, Numakawa T, Ninomiya M, *et al.* Behavioral and molecular evidence for psychotropic effects in L-theanine. *Psychopharmacology.* 2012;219(4):1099-1109. doi: 10.1007/s00213-011-2440-z.

| SUSTAINABLE CULTIVATION | BENEFIT SHARING |



PHARMACEUTICALS
(PTY) LTD

RESEARCHED
DEVELOPED
MANUFACTURED
DISTRIBUTED



HG&H PHARMACEUTICALS (Pty) Ltd | (Reg. No. 2006/016555/07)

Moraine House | The Braes | 193 Bryanston Drive | Bryanston | 2191 | Johannesburg | South Africa | PO Box 71931 | Bryanston | 2021

+27 (0) 10 020 7244 | info@zembrin.com | www.zembrin.com